These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
326 related articles for article (PubMed ID: 23178295)
1. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Launay D; Sitbon O; Hachulla E; Mouthon L; Gressin V; Rottat L; Clerson P; Cordier JF; Simonneau G; Humbert M Ann Rheum Dis; 2013 Dec; 72(12):1940-6. PubMed ID: 23178295 [TBL] [Abstract][Full Text] [Related]
2. Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Chung L; Domsic RT; Lingala B; Alkassab F; Bolster M; Csuka ME; Derk C; Fischer A; Frech T; Furst DE; Gomberg-Maitland M; Hinchcliff M; Hsu V; Hummers LK; Khanna D; Medsger TA; Molitor JA; Preston IR; Schiopu E; Shapiro L; Silver R; Simms R; Varga J; Gordon JK; Steen VD Arthritis Care Res (Hoboken); 2014 Mar; 66(3):489-95. PubMed ID: 23983198 [TBL] [Abstract][Full Text] [Related]
3. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Humbert M; Yaici A; de Groote P; Montani D; Sitbon O; Launay D; Gressin V; Guillevin L; Clerson P; Simonneau G; Hachulla E Arthritis Rheum; 2011 Nov; 63(11):3522-30. PubMed ID: 21769843 [TBL] [Abstract][Full Text] [Related]
4. Long-Term Outcomes in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS). Kolstad KD; Li S; Steen V; Chung L; Chest; 2018 Oct; 154(4):862-871. PubMed ID: 29777655 [TBL] [Abstract][Full Text] [Related]
5. Survival in systemic sclerosis with pulmonary arterial hypertension has not improved in the modern era. Rubenfire M; Huffman MD; Krishnan S; Seibold JR; Schiopu E; McLaughlin VV Chest; 2013 Oct; 144(4):1282-1290. PubMed ID: 23744060 [TBL] [Abstract][Full Text] [Related]
6. A prospective study of the 6 min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naïve systemic sclerosis-associated pulmonary arterial hypertension. Sanges S; Launay D; Rhee RL; Sitbon O; Hachulla É; Mouthon L; Guillevin L; Rottat L; Montani D; De Groote P; Cottin V; Magro P; Prévot G; Bauer F; Bergot E; Chabanne C; Reynaud-Gaubert M; Leroy S; Canuet M; Sanchez O; Gut-Gobert C; Dauphin C; Pison C; Boissin C; Habib G; Clerson P; Conesa F; Cordier JF; Kawut SM; Simonneau G; Humbert M Ann Rheum Dis; 2016 Aug; 75(8):1457-65. PubMed ID: 26324844 [TBL] [Abstract][Full Text] [Related]
7. Survival in systemic sclerosis associated pulmonary arterial hypertension in the current treatment era-results from a nationwide study. Sarı A; Satış H; Ayan G; Küçükşahin O; Kalyoncu U; Fidancı AA; Ayvalı MO; Ata N; Ülgü MM; Birinci Ş; Akdoğan A Clin Rheumatol; 2024 Jun; 43(6):1919-1925. PubMed ID: 38676757 [TBL] [Abstract][Full Text] [Related]
8. Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. Lefèvre G; Dauchet L; Hachulla E; Montani D; Sobanski V; Lambert M; Hatron PY; Humbert M; Launay D Arthritis Rheum; 2013 Sep; 65(9):2412-23. PubMed ID: 23740572 [TBL] [Abstract][Full Text] [Related]
9. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Condliffe R; Kiely DG; Peacock AJ; Corris PA; Gibbs JS; Vrapi F; Das C; Elliot CA; Johnson M; DeSoyza J; Torpy C; Goldsmith K; Hodgkins D; Hughes RJ; Pepke-Zaba J; Coghlan JG Am J Respir Crit Care Med; 2009 Jan; 179(2):151-7. PubMed ID: 18931333 [TBL] [Abstract][Full Text] [Related]
10. Prognostic factors of mortality and 2-year survival analysis of systemic sclerosis with pulmonary arterial hypertension in Thailand. Foocharoen C; Nanagara R; Kiatchoosakun S; Suwannaroj S; Mahakkanukrauh A Int J Rheum Dis; 2011 Aug; 14(3):282-9. PubMed ID: 21816025 [TBL] [Abstract][Full Text] [Related]
12. Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic Sclerosis. Moinzadeh P; Bonella F; Oberste M; Weliwitage J; Blank N; Riemekasten G; Müller-Ladner U; Henes J; Siegert E; Günther C; Kötter I; Pfeiffer C; Schmalzing M; Zeidler G; Korsten P; Susok L; Juche A; Worm M; Jandova I; Ehrchen J; Sunderkötter C; Keyßer G; Ramming A; Schmeiser T; Kreuter A; Lorenz HM; Hunzelmann N; Kreuter M Chest; 2024 Jan; 165(1):132-145. PubMed ID: 37582424 [TBL] [Abstract][Full Text] [Related]
13. Idiopathic and Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: A Comparison of Demographic, Hemodynamic, and MRI Characteristics and Outcomes. Ramjug S; Hussain N; Hurdman J; Billings C; Charalampopoulos A; Elliot CA; Kiely DG; Sabroe I; Rajaram S; Swift AJ; Condliffe R Chest; 2017 Jul; 152(1):92-102. PubMed ID: 28223154 [TBL] [Abstract][Full Text] [Related]
14. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease. Chauvelot L; Gamondes D; Berthiller J; Nieves A; Renard S; Catella-Chatron J; Ahmad K; Bertoletti L; Camara B; Gomez E; Launay D; Montani D; Mornex JF; Prévot G; Sanchez O; Schott AM; Subtil F; Traclet J; Turquier S; Zeghmar S; Habib G; Reynaud-Gaubert M; Humbert M; Cottin V Arthritis Rheumatol; 2021 Feb; 73(2):295-304. PubMed ID: 32892515 [TBL] [Abstract][Full Text] [Related]
15. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974 [TBL] [Abstract][Full Text] [Related]
16. [Risk factors for death and the clinical features of different subtypes of patients with pulmonary arterial hypertension related to congenital heart disease]. Xu ZY; Li QQ; Zhang C; Zhang HS; Gu H Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr; 48(4):315-322. PubMed ID: 32370483 [No Abstract] [Full Text] [Related]
17. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Mathai SC; Hummers LK; Champion HC; Wigley FM; Zaiman A; Hassoun PM; Girgis RE Arthritis Rheum; 2009 Feb; 60(2):569-77. PubMed ID: 19180517 [TBL] [Abstract][Full Text] [Related]
19. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan. Rotondo C; Praino E; Nivuori M; di Serio F; Lapadula G; Iannone F Int J Rheum Dis; 2017 Jan; 20(1):90-96. PubMed ID: 26218502 [TBL] [Abstract][Full Text] [Related]
20. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Campo A; Mathai SC; Le Pavec J; Zaiman AL; Hummers LK; Boyce D; Housten T; Champion HC; Lechtzin N; Wigley FM; Girgis RE; Hassoun PM Am J Respir Crit Care Med; 2010 Jul; 182(2):252-60. PubMed ID: 20339143 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]